Plant Compound Eriodictyol Blocks Bone Loss by Triggering Cellular Cleanup
Eriodictyol targets the LDHB enzyme to activate mitophagy and suppress the NLRP3 inflammasome, protecting bone mass in mice.
Summary
Eriodictyol (ERI), a natural flavonoid found in citrus and herbs, has been identified as a direct inhibitor of the enzyme lactate dehydrogenase B (LDHB) in bone-resorbing cells called osteoclasts. By binding to LDHB, ERI triggers mitophagy — the cellular process of clearing damaged mitochondria — which in turn reduces reactive oxygen species and shuts down the NLRP3 inflammasome, a key driver of inflammatory bone destruction. In laboratory studies, ERI suppressed osteoclast activity and bone resorption. In mice with LPS-induced bone loss, ERI significantly preserved bone density as confirmed by micro-CT and histology. The findings suggest eriodictyol could serve as a natural therapeutic candidate for osteoporosis and other bone loss conditions driven by chronic inflammation and osteoclast overactivation.
Detailed Summary
Bone loss disorders such as osteoporosis affect millions of aging adults and are driven by an imbalance between bone-building osteoblasts and bone-resorbing osteoclasts. Chronic low-grade inflammation — increasingly recognized as a hallmark of aging — amplifies osteoclast activity and accelerates bone deterioration. This study investigates eriodictyol (ERI), a naturally occurring flavonoid, as a novel intervention targeting this inflammatory cascade at the molecular level.
Researchers from Guangxi Medical University combined transcriptomic profiling, protein interaction assays, and in vivo mouse modeling to decode ERI's mechanism of action. RNA sequencing of osteoclasts treated with ERI revealed suppression of pathways linked to mitochondrial autophagy (mitophagy) and the NLRP3 inflammatory complex. Using molecular docking, surface plasmon resonance, and cellular thermal shift assays, the team confirmed that ERI directly and stably binds lactate dehydrogenase B (LDHB), an enzyme involved in cellular energy metabolism.
Functional experiments showed that LDHB expression levels governed osteoclast activity: silencing LDHB mimicked ERI's effects while overexpressing it reversed them, establishing a clear LDHB-dependent mechanism. By inhibiting LDHB, ERI promoted PINK1/Parkin-mediated mitophagy — the selective removal of dysfunctional mitochondria — which reduced reactive oxygen species (ROS) and consequently inactivated the NLRP3 inflammasome. This cascade reduced osteoclast-driven bone resorption in cell culture models.
In vivo, mice with LPS-induced systemic bone loss treated with ERI showed significantly preserved bone mass on micro-CT imaging and reduced inflammatory histological markers, validating the translational potential of the findings.
For aging adults and clinicians, eriodictyol represents an intriguing supplement candidate for protecting bone health through an anti-inflammatory, mitophagy-enhancing mechanism. However, these are preclinical findings only, and human pharmacokinetic and clinical data are lacking. The summary is based on the abstract only, as the full paper was not accessible.
Key Findings
- Eriodictyol directly binds and inhibits LDHB in osteoclasts, suppressing bone resorption in a LDHB-dependent manner.
- ERI activates PINK1/Parkin-mediated mitophagy, clearing damaged mitochondria and reducing ROS production.
- Mitophagy induction by ERI shuts down NLRP3 inflammasome activation, dampening inflammatory bone destruction.
- In LPS-induced bone loss mice, ERI significantly preserved bone density as shown by micro-CT and histology.
- LDHB silencing recapitulated ERI's bone-protective effects, confirming it as the primary molecular target.
Methodology
Study used in vitro osteoclast assays (CCK-8, TRAcP staining, SEM, RNA-seq, western blotting), molecular binding assays (molecular docking, SPR, CETSA), and LDHB gain/loss-of-function experiments. In vivo validation used an LPS-induced mouse bone loss model with micro-CT and histological immunostaining. The summary is based on the abstract only.
Study Limitations
All data are preclinical (cell culture and mouse models), with no human pharmacokinetic, safety, or efficacy data available. The LPS-induced bone loss model may not fully replicate postmenopausal or age-related osteoporosis. The summary is based on the abstract only and the full methods and data cannot be independently assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: